The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)—PISCES study, NCT 01064310.
Bernard J. Escudier
Consultant or Advisory Role - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer
Camillo Porta
Consultant or Advisory Role - Bayer; GlaxoSmithKline; Novartis; Pfizer; Roche
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pfizer; Roche
Research Funding - Bayer; Novartis
Petri Bono
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Expert Testimony - GlaxoSmithKline
Ugo De Giorgi
No relevant relationships to disclose
Omi Parikh
Consultant or Advisory Role - GlaxoSmithKline
Robert E. Hawkins
Consultant or Advisory Role - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline (I)
Honoraria - GlaxoSmithKline
Expert Testimony - GlaxoSmithKline
Emmanuel Sevin
No relevant relationships to disclose
Sylvie Negrier
Honoraria - GlaxoSmithKline; Novartis; Pfizer; Roche
Research Funding - GlaxoSmithKline; Roche
Sadya Khan
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Lauren McCann
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Faisal Mehmud
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
David Cella
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - GlaxoSmithKline